Table 1.
Baseline Characteristics by Age Group and Treatment
| Age: <65 Years (N=766) | Age: 65 to 74 (N=1130) | Age: ≥75 Years (N=308) | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Characteristics | Ablation (N=375) | Drug (N=391) | Ablation (N=577) | Drug (N=553) | Ablation (N=156) | Drug (N=152) |
| Age | ||||||
| N | 375 | 391 | 577 | 553 | 156 | 152 |
| Median (Q1, Q3) | 59.2 (54.3, 62.1) | 59.4 (55.7, 62.6) | 69.3 (67.3, 71.8) | 69.3 (67.2, 71.9) | 77.6 (76.5, 80.0) | 77.3 (76.0, 79.4) |
| Female Sex | 94/375 (25.1%) | 104/391 (26.6%) | 234/577 (40.6%) | 234/553 (42.3%) | 85/156 (54.5%) | 68/152 (44.7%) |
| Minorities | 54/375 (14.4%) | 51/389 (13.1%) | 47/574 (8.2%) | 49/553 (8.9%) | 12/155 (7.7%) | 12/152 (7.9%) |
| History of CVA or TIA | 48/375 (12.8%) | 32/390 (8.2%) | 50/577 (8.7%) | 52/553 (9.4%) | 19/156 (12.2%) | 19/152 (12.5%) |
| History of Heart Failure | 64/375 (17.1%) | 68/389 (17.5%) | 80/577 (13.9%) | 74/553 (13.4%) | 30/156 (19.2%) | 21/152 (13.8%) |
| NYHA Class II or Greater | 130/373 (34.9%) | 154/388 (39.7%) | 184/569 (32.3%) | 179/551 (32.5%) | 64/155 (41.3%) | 67/150 (44.7%) |
| CHA2DS2-VASc > 2 | 117/375 (31.2%) | 113/391 (28.9%) | 359/577 (62.2%) | 364/553 (65.8%) | 151/156 (96.8%) | 141/152 (92.8%) |
| Type of AF At Enrollment | ||||||
| Paroxysmal | 159/375 (42.4%) | 155/390 (39.7%) | 247/577 (42.8%) | 263/553 (47.6%) | 64/156 (41.0%) | 58/152 (38.2%) |
| Persistent and Longstanding Persistent | 216/375 (57.6%) | 235/390 (60.3%) | 330/577 (57.2%) | 290/553 (52.4%) | 92/156 (59.0%) | 94/152 (61.8%) |
| Mitral Valve Regurgitation | 129/304 (42.4%) | 127/296 (42.9%) | 210/426 (49.3%) | 191/362 (52.8%) | 66/109 (60.6%) | 53/99 (53.5%) |
| Diastolic Dysfunction | 30/243 (12.3%) | 41/255 (16.1%) | 43/308 (14.0%) | 39/308 (12.7%) | 15/84 (17.9%) | 21/80 (26.3%) |
| LVH | 145/314 (46.2%) | 166/304 (54.6%) | 143/436 (32.8%) | 121/374 (32.4%) | 46/114 (40.4%) | 41/102 (40.2%) |
| Prior use of anti-arrhythmic drug | 174/355 (49.0%) | 183/368 (49.7%) | 249/547 (45.5%) | 289/534 (54.1%) | 68/145 (46.9%) | 79/146 (54.1%) |
| Prior revascularization (PCI or CABG) | 29/375 (7.7%) | 41/390 (10.5%) | 65/577 (11.3%) | 69/553 (12.5%) | 37/156 (23.7%) | 23/152 (15.1%) |
| Diabetes | 111/375 (29.6%) | 117/390 (30.0%) | 139/577 (24.1%) | 131/553 (23.7%) | 30/156 (19.2%) | 33/152 (21.7%) |
| Prior Stroke | 26/375 (6.9%) | 17/390 (4.4%) | 33/577 (5.7%) | 33/553 (6.0%) | 9/156 (5.8%) | 8/152 (5.3%) |
| Prior use of DOAC | 231/375 (61.6%) | 259/391 (66.2%) | 364/577 (63.1%) | 325/553 (58.8%) | 94/156 (60.3%) | 104/152 (68.4%) |
| Hypertension | 305/375 (81.3%) | 344/390 (88.2%) | 440/577 (76.3%) | 434/553 (78.5%) | 131/156 (84.0%) | 122/152 (80.3%) |
| BMI | ||||||
| N | 374 | 384 | 560 | 548 | 152 | 152 |
| Median (Q1, Q3) | 31.9 (27.6, 36.4) | 31.7 (28.2, 36.6) | 29.7 (26.7, 33.7) | 30.0 (26.4, 34.6) | 27.6 (24.7, 31.3) | 27.6 (25.2, 31.1) |
| Left Atrial Diameter | ||||||
| N | 210 | 228 | 270 | 258 | 72 | 70 |
| Median (Q1, Q3) | 4.6 (4.1, 5.1) | 4.6 (4.2, 5.2) | 4.4 (4.0, 4.9) | 4.3 (3.9, 4.8) | 4.4 (3.8, 4.6) | 4.5 (4.0, 4.9) |
| Left Atrial Volume Index | ||||||
| N | 75 | 66 | 104 | 105 | 23 | 17 |
| Median (Q1, Q3) | 41.0 (32.0, 50.0) | 40.4 (35.3, 48.0) | 39.0 (29.9, 48.7) | 36.0 (27.7, 44.2) | 42.0 (30.7, 56.0) | 34.0 (33.0, 47.0) |
| Years since onset of AF | ||||||
| N | 373 | 383 | 576 | 551 | 151 | 151 |
| Median (Q1, Q3) | 1.3 (0.4, 4.3) | 1.1 (0.3, 3.7) | 1.0 (0.3, 3.9) | 1.1 (0.3, 3.8) | 0.8 (0.2, 4.1) | 0.8 (0.2, 3.5) |
AF=atrial fibrillation, BMI=body mass index, CABG=coronary artery bypass graft surgery, CVA=cerebrovascular accident, DOAC=direct oral anticoagulants, LVH=left ventricular hypertrophy, NYHA=New York Heart Association, PCI=percutaneous coronary intervention, Q1=1st quartile, Q3=3rd quartile, TIA=transient ischemic attack,